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Abstract We report on the structural background of the
remarkable reduction of allergenicity in engineering of the major
house dust mite allergen Der f 2. Disruption of intramolecular
disulfide bonds in Der f 2 caused extensive conformational
change that was monitored by circular dichroism and gel-
filtration analysis. The degree of conformational change
correlated well with the degree of reductions in the capacity to
bind IgE and to induce histamine release from basophils in mite-
allergic patients. Loosening the rigid tertiary structure by
elimination of key intramolecular interactions is an effective
strategy to reduce the number of high affinity IgE epitopes of
allergen vaccine. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Type I allergic diseases mediated by IgE against allergens
such as asthma, rhinitis and atopic dermatitis a¡ect more than
20% of the world’s population. Allergen-speci¢c immunother-
apy involves repeated injection of allergen vaccine over pro-
longed periods to achieve a state of immunological tolerance
[1] and has proven an e¡ective treatment of allergic disease
since the ¢rst trials in the early 1900s [2]. The major problem
with allergen-speci¢c immunotherapy, however, is the risk of
an anaphylactic reaction. Recently, the use of hypoallergenic
natural isoforms [3], engineered recombinant mutants [4^7], or
non-anaphylactic recombinant fragments [8^10] of several al-
lergens from house dust mite, tree pollen, and grass pollen has
been proposed to reduce the allergenicity [11^13]. ‘Allergen
engineering’ achieves a reduction of IgE-binding capacities
of the allergen proteins by introducing site-directed mutations
to the amino acid sequences of the recombinant allergens [4^
7]. Ideally, the engineered allergens do not crosslink the com-
plex of allergen-speci¢c IgE and high a⁄nity IgE receptor
(FcORI) on the surface of mast cells and basophils, nor induce
the release of mediators from the cells [14,15].
The major causative factors associated with various allergic
diseases are house dust mite (Dermatophagoides farinae and
Dermatophagoides pteronyssinus) allergens [16^19]. The major
allergens from house dust mite are classi¢ed as group 1 (Der f
1 and Der p 1, Mr 25 000) or group 2 (Der f 2 and Der p 2,
Mr 14 000) [20^25]. Der f 2 is the major group 2 allergen from
D. farinae [26,27], and consists of 129 amino acid residues
with marked homology to Der p 2 [28], the group 2 allergen
from D. pteronyssinus. We determined the location of three
disul¢de bonds of native Der f 2 (Cys8^Cys119, Cys21^Cys27
and Cys73^Cys78) [29] and the tertiary structure of recombi-
nant Der f 2 by nuclear magnetic resonance [30].
Allergen engineering of Der f 2 has revealed that two disul-
¢de bonds, Cys8^Cys119 and Cys73^Cys78, are critical to the
IgE-binding capacity of Der f 2 [4,31,32]. Understanding of
the structural background of the reduced allergenicity in en-
gineered allergen mutants is important for development of
e¡ective strategies for allergen engineering. In this study, we
focus on the background of the remarkable reduction of IgE-
binding capacity in Der f 2 mutants. We demonstrate that
disruption of disul¢de bonds in Der f 2 caused remarkable
conformational changes and that reductions in allergenic ac-
tivities were dependent on the degree of change.
2. Materials and methods
2.1. Expression of the wild-type and cysteine mutants of Der f 2
Expression vectors for the wild-type Der f 2 and its three mutants,
C21/27S, C73/78S, and C8/119S, were constructed as previously de-
scribed [4]. Those for 8C-119C and vC were constructed by the use of
restriction sites and site-directed mutagenesis in this study. The wild-
type Der f 2 and its ¢ve mutants were expressed in Escherichia coli
BL21 (DE3) transformed with the expression vectors.
2.2. Puri¢cation of the wild-type and cysteine mutants of Der f 2
The wild-type and mutants of Der f 2 produced as inclusion bodies
in E. coli BL21 (DE3) were recovered, solubilized with bu¡er contain-
ing urea, refolded by dialysis against bu¡er, and puri¢ed by anion
exchange column chromatography as described [4,31,33]. The disul¢de
bond formation of the puri¢ed recombinant wild-type and mutants of
Der f 2 was con¢rmed correct by peptide mapping as described [29].
The purities were checked by sodium dodecyl sulfate^polyacrylamide
gel electrophoresis (SDS^PAGE) under non-reducing or reducing con-
ditions.
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2.3. Gel-¢ltration analysis
The puri¢ed wild-type and mutants of Der f 2 (200 Wl, approximate
100 Wg/ml) were subjected to gel-¢ltration chromatography on a
Superdex 75 HR 10/30 (1 cmU30 cm) (Pharmacia, Uppsala, Sweden)
at a £ow rate of 1 ml/min with phosphate-bu¡ered saline (pH 7.4).
Absorbance at 280 nm was monitored. Molecular weight standards
for gel-¢ltration (Bio-Rad, Richmond, CA, USA) were used for esti-
mation of apparent molecular weights of the recombinant proteins.
2.4. Radioallergosorbent test-enzyme immunoassay (RAST-EIA)
IgE reactivities of the puri¢ed wild-type and mutants of Der f 2
were measured by RAST-EIA using a RAST-FEIA kit (Pharmacia) as
previously described [10]. Brie£y, serum of each allergic patient (1/2-1
dilution) was incubated with paper discs coupled with each of the
puri¢ed antigens in various amounts for 3 h at 37‡C. Then, the IgE
that bound to the disc was detected with L-galactosidase-conjugated
anti-human IgE antibodies by measuring the £uorescence. The sera
from patients allergic to house dust mite were kindly provided by Dr.
Hirokazu Okudaira, University of Tokyo.
2.5. Inhibition assay
The method was as described previously with some modi¢cations
[31]. Brie£y, the serum of each allergic patient (1/2-1 dilution) was
incubated with various concentrations of each of the puri¢ed wild-
type Der f 2 and its mutants for 3 h at room temperature, and then
the solution was added to a paper disc presoaked in wild-type Der f 2.
The IgE that bound to discs was detected with L-galactosidase-con-
jugated anti-human IgE antibodies. The percentage of inhibition was
expressed as the relative reduction of the £uorescence intensity in each
sample to that when no inhibitors were added.
Fig. 1. Puri¢ed Der f 2 mutants. (A) Con¢rmation of intramolecular disul¢de bonds. Schematic representation of native Der f 2 puri¢ed from
mite extract and the puri¢ed wild-type and ¢ve mutants of Der f 2 expressed in E. coli with a methionine at the ¢rst N-terminal residue are
shown with con¢rmed disul¢de bonds. (B) SDS^PAGE analysis under non-reducing and reducing conditions. WT: wild-type Der f 2. M: mo-
lecular weight marker. (C) Elution pro¢les in gel-¢ltration analysis. Apparent molecular weights of the peaks of puri¢ed wild-type and mutants
of Der f 2 are shown with arrows. The elution pro¢le of molecular weight standards is also shown as a control (STD).
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2.6. Histamine release
The method was as described previously except that a histamine
enzyme-linked immunosorbent assay (ICN, Costa Mesa, CA, USA)
was used [4]. The percentage of released histamine was calculated as
the relative amount of histamine in the supernatant to the total of
supernatant and cellular histamine.
2.7. Circular dichroism (CD)
CD spectra were measured on a JASCO J-700 spectropolarimeter
(Japan Spectroscopic Co., Ltd., Tokyo, Japan) using a 0.1 cm cell.
Spectra were recorded at 25‡C over 200^250 nm. Samples are 114
Wg/ml in 20 mM Tris^HCl, pH 7.4, and 0.9% NaCl.
3. Results
3.1. Preparation of puri¢ed Der f 2 mutants with correct
disul¢de bonds
We generated ¢ve mutants of Der f 2, in which one (C21/
27S, C73/78S, and C8/119S), two (8C-119C), or three (vC)
pairs of cysteines forming the intramolecular disul¢de bonds
were changed to a pair of serines (Fig. 1A). Each of the
puri¢ed wild-type Der f 2 and its mutants was detected as a
single band on SDS^PAGE under both non-reducing and re-
ducing conditions (Fig. 1B). Under non-reducing conditions,
mobilities of C8/119S and vC, in both of which Cys8^Cys119
was disrupted, were smaller than those of the wild-type Der f
2, C21/27S, C73/78S, and 8C-119C, in all of which Cys8^
Cys119 was conserved. Mobilities of the wild-type and all
mutants of Der f 2 under reducing conditions were equivalent
to those of C8/119S and vC under non-reducing conditions.
The correct disul¢de bond formations of the puri¢ed wild-
type and mutants of Der f 2 were con¢rmed by peptide map-
ping [29] (Fig. 1A).
Each of the puri¢ed mutants was detected as a single peak
in gel-¢ltration analysis (Fig. 1C). Interestingly, 8C-119C, C8/
119S and vC had prolonged elution times compared with the
wild-type Der f 2, C21/27S, and C73/78S. Apparent molecular
weights of the wild-type and mutants of Der f 2 in gel-¢ltra-
tion were calculated. The apparent molecular weights of the
wild-type Der f 2, C21/27S and C73/78S were approximately
15 kDa. The apparent molecular weights of 8C-119C, C8/119S
and vC were approximately 23 kDa, 35 kDa, and 40 kDa,
respectively.
3.2. Reactivities of puri¢ed Der f 2 mutants to IgE in allergic
patient sera
The IgE reactivities of the homogeneously puri¢ed recombi-
nant proteins with correct disul¢de bonds were determined by
RAST-EIA [10,31]. In two patients, TT and YI, the most
remarkable reduction was in vC followed by 8C-119C and
no or a signi¢cant but not remarkable reduction in C21/27S
(Fig. 2A). In the patient TT, C8/119S and C73/78S showed a
moderate reduction. In the patient YI, C8/119S showed a
remarkable reduction and C73/78S showed a moderate reduc-
Fig. 2. Reactivities of puri¢ed Der f 2 mutants to IgE in mite-aller-
gic patient sera. (A) IgE-binding pro¢les of two patients. (B) IgE-
binding pro¢les of 18 patients. The concentration of antigens in the
immobilization step was 600 ng/ml. Initials of the patients’ names
are indicated. WT: wild-type Der f 2.
Fig. 3. Inhibition of IgE-binding to the immobilized wild-type Der f
2 by addition of Der f 2 mutants. (A) Group A: C8/119S was re-
markably more reduced than C73/78S. (B) Group B: C8/119S was
slightly more reduced than C73/78S. (C) Group C: C73/78S was
more reduced than C8/119S. (D) Group D: C8/119S was weaker at
low concentrations but stronger at high concentrations than C73/
78S. The concentration of the wild-type Der f 2 in the immobiliza-
tion step was 100 ng/ml. Initials of the patients’ names are indi-
cated. WT: wild-type Der f 2.
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tion. Similar results were obtained in analysis of the IgE-bind-
ing pro¢les of 18 patients (Fig. 2B). A tendency existed in the
IgE-binding pro¢les; in order of IgE reactivity, the mutants
ranked C21/27SsC73/78SvC8/119Ss 8C-119CsvC. Al-
though there was a tendency that the reactivity of C8/119S
was lower than that of C73/78S, the range of the relative IgE
reactivity of C8/119S to C73/78S di¡ered to some extent; the
reactivity of C8/119S was equivalent with or slightly higher
than that of C73/78S in patients such as CM, MM, and TN.
3.3. Activities of puri¢ed Der f 2 mutants to inhibit IgE-binding
to immobilized wild-type Der f 2
The capacities of the mutants to inhibit IgE from binding to
the wild-type Der f 2 were also examined using the sera of
seven patients by inhibition assay (Fig. 3). In all patients, the
inhibitory e¡ect by vC was the most reduced and that by C21/
27S was equivalent to that by the wild-type Der f 2 or rela-
tively strong among the mutants. However, the inhibitory
pro¢les of the patients for the other three mutants, C73/78S,
C8/119S, and 8C-119C, were not the same. The patients were
classi¢ed into four groups based on a comparison of C8/119S
and C73/78S in inhibitory activity; group A: C8/119S was
remarkably weaker than C73/78S (three patients) (Fig. 3A),
group B: C8/119S was slightly weaker than C73/78S (two
patients) (Fig. 3B), group C: C73/78S was weaker than C8/
119S (one patient) (Fig. 3C), and group D: C8/119S was
weaker at low concentrations but stronger at high concentra-
tions than C73/78S (one patient) (Fig. 3D). Group D was
considered a mix of groups A, B, and C. In patients belonging
to group A, C8/119S was weaker than or equivalent to 8C-
119C in the inhibitory activity (Fig. 3A). On the other hand,
in patients belonging to groups B, C, or D, 8C-119C was the
second weakest after vC (Fig. 3B^D).
3.4. Activities of puri¢ed Der f 2 mutants to induce histamine
release from basophils
Peripheral blood basophils from an allergic patient, TT,
were stimulated with the wild-type and mutants of Der f 2,
and histamine release was measured (Fig. 4). Activities of all
the mutants were lower than that of the wild-type Der f 2. The
activity of vC was the most reduced. The threshold concen-
tration of vC (approximately 1 Wg/ml) to stimulate peripheral
basophils to release histamine was about 1000 times more
than that of the wild-type Der f 2 (approximately 0.001
Wg/ml), that of 8C-119C and C8/119S (0.1^1 Wg/ml) about
100^1000 times more, that of C73/78S (0.01^0.1 Wg/ml) about
10^100 times more, and that of C21/27S (0.001^0.01 Wg/ml)
about 1^10 times more.
3.5. Secondary structures of puri¢ed Der f 2 mutants
CD spectra of all the Der f 2 mutants were di¡erent from
that of the wild-type Der f 2 (Fig. 5A). The fractions of helical
structures were estimated by using the ellipticity at 222 nm
[34]. The calculated values of the helical content are as fol-
lows: wild-type Der f 2: 8.7%, C21/27S: 8.8%, C73/78S: 2.3%,
C8/119S: 3.7%, 8C-119C: 2.7%, and vC: 2.9%. Thus, the
estimated helical content of C21/27S was comparable with
that of the wild-type, and in the other four mutants disruption
of the helices was estimated to be similar to each other. There-
fore, the di¡erences in the region of 200^210 nm among these
four mutants could be attributed to transitions from L-struc-
tures to random coils, i.e. they ranked vCsC8/119S, 8C-
119CsC73/78S in order of disruption of the two L-sheets,
the main components of the wild-type Der f 2 [30].
4. Discussion
The set of ¢ve Der f 2 mutants each di¡ering in choice of
three intramolecular disul¢de bonds (Figs. 1A and 5B) used in
Fig. 4. Histamine release from basophils stimulated with the puri¢ed
Der f 2 mutants. Peripheral blood leukocytes were obtained from a
mite-allergic patient TT. WT: wild-type Der f 2.
Fig. 5. (A) CD spectra of the puri¢ed Der f 2 mutants. The experi-
mental parameters are: bandwidth 1.0 nm, sensitivity 20 m‡, step
resolution 0.2 nm/datum, scan speed 50 nm/min, and number of
scans 8. (B) Ribbon diagram of the mean structure of Der f 2 [30].
The disul¢de bonds and L-strands are shown. This ¢gure was pro-
duced by the program MOLSCRIPT [42] and Raster 3D [43].
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this study was a suitable model with which to examine the
structural background of the remarkable reduction of allerge-
nicity in mutant allergens engineered for improved allergen-
speci¢c immunotherapy. The mutants were puri¢ed to homo-
geneity, and con¢rmed to have the correct disul¢de bonds
(Fig. 2).
We have reported that two disul¢de bonds, Cys8^Cys119
and Cys73^Cys78, are critical to the IgE-binding capacity of
Der f 2 by analyzing the allergenicities of C21/27S, C73/78S,
and C8/119S [4]. In CD spectra, C8/119S and C73/78S di¡ered
remarkably from that of the wild-type Der f 2 but C21/27S
less so (Fig. 5A). Additional disruption of disul¢de bonds in
vC, in which all three disul¢de bonds were disrupted, and 8C-
119C, in which only one disul¢de bond, Cys8^Cys119, was
conserved, led to disruption of the secondary structure and
further reductions in IgE reactivity (Figs. 2, 3 and 5). Fur-
thermore, increases of the apparent molecular weight in vC,
C8/119S, and 8C-119C were observed in gel-¢ltration analysis
(Fig. 1C). vC, C8/119S, and 8C-119C have apparent molec-
ular weight of approximately 2.7-, 2.3-, and 1.5-fold that of
wild-type Der f 2, respectively. The major house dust mite
group 2 allergens, Der f 2 and Der p 2, are single-domain
proteins which are mainly composed of two L-sheets (Fig.
5B) [30,35]. The loosening of the rigid structure in the three
mutants corresponds well to the disruption of the L-sheets
detected by CD (Fig. 5). Additionally, Der p 2 was reported
to have a short helix at residues 72^75 [35], and Der f 2 also
has a helix-like structure at the corresponding position (resi-
dues 72^76) although it is not explicitly described [30]. We
conclude that, in vC, C8/119S, and 8C-119C, global structural
change caused the remarkable reduction of IgE reactivity,
while in C73/78S, the disruption of the helix 72^76 a¡ected
the IgE reactivity.
IgE reactivity as detected by binding assay is considered
dependent on the number of IgE epitopes immobilized on
the disc which have enough a⁄nity not to be washed out
during the assay (Fig. 2). A tendency existed in the IgE-bind-
ing pro¢les, i.e. in order of IgE reactivity the mutants ranked
C21/27SsC73/78SvC8/119Ss 8C-119CsvC (Fig. 2B). But
the range of the relative IgE reactivities of C8/119S to C73/
78S di¡ered to some extent. These results suggest that the IgE
recognition pro¢les of patients allergic to Der f 2 have sim-
ilarity but are not completely uniform. The lower IgE-binding
of C8/119S than C73/78S in the majority of sera is considered
to result from remarkable disruption of the L-sheet structure
and the global folding (Figs. 1C and 5A). IgE-binding of C73/
78S equivalent to or lower than C8/119S in patients such as
CM, MM, and TN is considered to result from more complete
disruption of IgE epitopes around Cys73^Cys78 in C73/78S
(Figs. 2 and 3C). However, in vC and 8C-119C, on the dis-
ruption of one more disul¢de bond to C8/119S and C73/78S,
the diversity was lost and a much more complete elimination
of the IgE reactivity was achieved in all patients (Fig. 2).
IgE reactivity detected by inhibition assay is considered de-
pendent on the relative number and relative a⁄nity of serum
heterogeneous IgE molecules which bind the inhibitor to those
of the IgE molecules which bind wild-type Der f 2 (Fig. 3). At
higher inhibitor concentrations, where the number of mutant
Der f 2 molecules can override attenuation of binding a⁄nity,
the reactivity is considered to re£ect mainly the relative num-
ber of IgE molecules that each inhibitor can absorb. vC had
no or very little inhibitory activity in all patients. A similar
phenomenon was observed in 8C-119C. We considered that
the disruption of three or two disul¢de bonds in vC or 8C-
119C synergistically perturbed or disrupted the conformations
of many IgE epitopes. In patients belonging to group A, in-
hibitory activity of 8C-119C was higher than or equivalent to
C8/119S (Fig. 3A). In these patients, the number of IgE epi-
topes maintained by Cys8^Cys119 in 8C-119C is considered to
be larger than or equivalent to that of IgE epitopes main-
tained by Cys73^Cys78 in C8/119S.
In one patient, TT, C8/119S had less inhibitory activity
than C73/78S at low concentrations but more at high concen-
trations (Fig. 3D). In this patient, C8/119S had signi¢cantly
less activity to release histamine from basophils than C73/78S
(Fig. 4). These results suggest that the number of IgE epitopes
with high a⁄nity is critical to whether the cells degranulate in
the immediate phase. Torigoe et al. reported that aggregation
of IgE^FcORI complexes on mast cells with low a⁄nity li-
gands for IgE was ine¡ective in completing the signal trans-
duction cascades to induce degranulation of the cells [36,37].
The activity of vC to stimulate basophils to release histamine
was about 1000 times less than that of the wild-type Der f 2,
and the activity of 8C-119C and of C8/119S about 100^1000
times less (Fig. 4). The number of IgE epitopes with a⁄nity
high enough to induce cell degranulation was considered to be
markedly reduced in the mutants, vC, 8C-119C, and, C8/
119S, in which global compactness was disrupted (Figs. 1C
and 5A).
Smith et al. reported that a mutant of Der p 2 from D.
pteronyssinus, C73R, expressed as a fused form with a histi-
dine-tag in E. coli, had around 10 times less activity than wild-
type Der p 2 to induce an immediate reaction in a skin test in
three patients and around 100 times less activity in two pa-
tients [7]. This is consistent with our result that the histamine-
releasing activity of a mutant of Der f 2, C73/78S, was about
10^100 times less than that of wild-type Der f 2 in this study
(Fig. 4). Disruption of the helix 72^75 might have occurred in
their Der p 2 mutant, C73R, as was con¢rmed in our Der f 2
mutant, C73/78S (Fig. 5A).
The structural changes to engineered allergen mutants were
de¢ned for the ¢rst time in this study. Ferreira et al. reported
on a hypoallergenic mutant of the major birch pollen allergen
Bet v 1, in which six amino acid substitutions were introduced
[5]. Their strategy is based on the comparative analysis of
sequences of natural hypoallergenic variants [3], and there-
fore, the engineered hypoallergenic mutant maintained a sec-
ondary structure similar to that of the allergenic wild-type Bet
v 1. However, natural hypoallergenic variants such as those of
Bet v 1 are not observed in general [13]. On the other hand,
the disruption of tertiary and/or secondary structures of
allergens de¢ned in this study is considered a strategy widely
adaptive to various allergens. Furthermore, the disruption of
tertiary and/or secondary structures would particularly reduce
the number of epitopes with high a⁄nity to IgE and be a
more e¡ective strategy than direct targeting of each IgE epi-
tope on the surface of the allergen. The tertiary and secondary
structures of proteins are maintained by various intramolecu-
lar interactions. Some of these interactions might be critical to
maintaining the correct folding or for the folding process
itself. Disul¢de bond formation targeted in this study is a
typical intramolecular interaction in protein. In allergen
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engineering based on this strategy, information on the tertiary
structure of allergens might be useful for screening key intra-
molecular interactions other than disul¢de bonds [30,38].
We showed that the degree of the tertiary and/or secondary
conformational change correlated well with the degree of re-
duction in the capacity to bind IgE and to induce histamine
release from basophils. A mutant, C8/119S, in which compact-
ness of the global structure is disrupted has been analyzed for
T-cell reactivity [4], IgE-binding, and skin prick tests [39,40] in
a larger population of patients and the administration of C8/
119S has been shown to suppress an immediate allergic reac-
tion in mice [41]. Loosening of the rigid tertiary structure by
elimination of key intramolecular interactions in the allergen
molecule would be an e¡ective strategy in allergen engineering
adaptive to various allergens for safe and e¡ective allergen-
speci¢c immunotherapy.
Acknowledgements: We would like to thank Dr. Hirokazu Okudaira,
University of Tokyo, for patients’ sera, Dr. Masataka Horiuchi, To-
kyo Metropolitan Institute of Medical Science, for technical advice
concerning CD, and Hiroshi Sugiyama, Asahi Breweries, Ltd., for
technical advice concerning peptide mapping.
References
[1] Norman, P.S. (1993) Curr. Opin. Immunol. 5, 968^973.
[2] Noon, L. (1911) Lancet i, 1572^1573.
[3] Ferreira, F., Hirtenlehner, K., Jilek, A., Godnik-Cvar, J., Breite-
neder, H., Grimm, R., Ho¡mann-Sommergruber, K., Scheiner,
O., Kraft, D., Breitenbach, M., Rheinberger, H.J. and Ebner, C.
(1996) J. Exp. Med. 183, 599^609.
[4] Takai, T., Yokota, T., Yasue, M., Nishiyama, C., Yuuki, T.,
Mori, A., Okudaira, H. and Okumura, Y. (1997) Nat. Biotech-
nol. 15, 754^758.
[5] Ferreira, F., Ebner, C., Kramer, B., Casari, G., Briza, P., Kungl,
A.J., Grimm, R., Jahn-Schmid, B., Breiteneder, H., Kraft, D.,
Breitenbach, M., Rheinberger, H.J. and Scheiner, O. (1998) FA-
SEB J. 12, 231^242.
[6] Okada, T., Swoboda, I., Bhalla, P.L., Toriyama, K. and Singh,
M.B. (1998) FEBS Lett. 434, 255^260.
[7] Smith, A.M., Chapman, M.D., Taketomi, E.A., Platts-Mills,
T.A. and Sung, S.S. (1998) J. Allergy Clin. Immunol. 101, 423^
425.
[8] Vrtala, S., Hirtenlehner, K., Vangelista, L., Pastore, A., Eichler,
H.G., Sperr, W.R., Valent, P., Ebner, C., Kraft, D. and Valenta,
R. (1997) J. Clin. Invest. 99, 1673^1681.
[9] Schramm, G., Kahlert, H., Suck, R., Weber, B., Stuwe, H.T.,
Muller, W.D., Bufe, A., Becker, W.M., Schlaak, M.W., Jager,
L., Cromwell, O. and Fiebig, H. (1999) J. Immunol. 162, 2406^
2414.
[10] Takai, T., Mori, A., Yuuki, T., Okudaira, H. and Okumura, Y.
(1999) Mol. Immunol. 36, 1055^1065.
[11] Kraft, D., Ferreira, F., Ebner, C., Valenta, R., Breiteneder, H.,
Susani, M., Breitenbach, M. and Scheiner, O. (1998) Allergy 53,
62^66.
[12] Valenta, R., Almo, S., Ball, T., Dolecek, C., Steinberger, P.,
La¡er, S., Eibensteiner, P., Flicker, S., Vrtala, S., Spitzauer, S.,
Valent, P., Denepoux, S., Kraft, D., Banchereau, J. and Lebec-
que, S. (1998) Int. Arch. Allergy Immunol. 116, 167^176.
[13] Singh, M.B., de Weerd, N. and Bhalla, P.L. (1999) Int. Arch.
Allergy Immunol. 119, 75^85.
[14] Ishizaka, T. and Ishizaka, K. (1984) Prog. Allergy 34, 188^235.
[15] Metzger, H., Alcaraz, G., Hohman, R., Kinet, J.P., Pribluda, V.
and Quarto, R. (1986) Annu. Rev. Immunol. 4, 419^470.
[16] Platts-Mills, T.A.E. and Weck, A.L. (1989) J. Allergy Clin. Im-
munol. 83, 755^775.
[17] Voorhorst, R., Spieksma, F.T.M., Vanekamp, M.J., Leupen,
M.J. and Lyklema, A.W. (1967) J. Allergy 39, 325^328.
[18] Miyamoto, T., Oshima, S., Ishizaki, T. and Sato, S.H. (1968)
J. Allergy 42, 14^28.
[19] Tovey, E.R., Chapman, M.D. and Platts-Mills, T.A. (1981) Na-
ture 289, 592^593.
[20] Thomas, W.R. and Smith, W. (1998) Allergy 53, 821^832.
[21] Chapman, M.D. and Platts-Mills, T.A. (1980) J. Immunol. 125,
587^592.
[22] Haida, M., Okudaira, H., Ogita, T., Ito, K., Miyamoto, T., Na-
kajima, T. and Hongo, O. (1985) J. Allergy Clin. Immunol. 75,
686^692.
[23] Yasueda, H., Mita, H., Yui, Y. and Shida, T. (1986) Int. Arch.
Allergy Appl. Immunol. 81, 214^223.
[24] Yamashita, N., Haida, M., Suko, M., Okudaira, H. and Miya-
moto, T. (1989) Int. Arch. Allergy Appl. Immunol. 88, 173^175.
[25] Yasueda, H., Mita, H., Yui, Y. and Shida, T. (1989) Int. Arch.
Allergy Appl. Immunol. 88, 402^407.
[26] Yuuki, T., Okumura, Y., Ando, T., Yamakawa, H., Suko, M.,
Haida, M. and Okudaira, H. (1990) Jpn. J. Allergol. 39, 557^561.
[27] Yuuki, T., Okumura, Y., Ando, T., Yamakawa, H., Suko, M.,
Haida, M. and Okudaira, H. (1991) Agric. Biol. Chem. 55, 1233^
1238.
[28] Chua, K.Y., Doyle, C.R., Simpson, R.J., Turner, K.J., Stewart,
G.A. and Thomas, W.R. (1990) Int. Arch. Allergy Appl. Immu-
nol. 91, 118^123.
[29] Nishiyama, C., Yuuki, T., Takai, T., Okumura, Y. and Oku-
daira, H. (1993) Int. Arch. Allergy Immunol. 101, 159^166.
[30] Ichikawa, S., Hatanaka, H., Yuuki, T., Iwamoto, N., Kojima, S.,
Nishiyama, C., Ogura, K., Okumura, Y. and Inagaki, F. (1998)
J. Biol. Chem. 273, 356^360.
[31] Nishiyama, C., Fukada, M., Usui, Y., Iwamoto, N., Yuuki, T.,
Okumura, Y. and Okudaira, H. (1995) Mol. Immunol. 32, 1021^
1029.
[32] Takai, T., Yuuki, T., Okumura, Y., Mori, A. and Okudaira, H.
(1997) Mol. Immunol. 34, 255^261.
[33] Nishiyama, C., Yuuki, T., Usui, Y., Iwamoto, N., Okumura, Y.
and Okudaira, H. (1994) Int. Arch. Allergy Immunol. 105, 62^69.
[34] Chen, Y.H., Yang, J.T. and Martinez, H.M. (1972) Biochemistry
11, 4120^4131.
[35] Mu«eller, G.A., Benjamin, D.C. and Rule, G.S. (1998) Biochem-
istry 37, 12707^12714.
[36] Torigoe, C., Inman, J.K. and Metzger, H. (1998) Science 281,
568^572.
[37] Malissen, B. (1998) Science 281, 528^529.
[38] Gajhede, M., Osmark, P., Poulsen, F.M., Ipsen, H., Larsen, J.N.,
Joost van Neerven, R.J., Schou, C., LÖwenstein, H. and Spang-
fort, M.D. (1996) Nat. Struct. Biol. 3, 1040^1045.
[39] Kusunoki, T., Inoue, Y., Korematsu, S., Harazaki, M., Yokota,
T. and Hosoi, S. (2000) Ann. Allergy Asthma Immunol. 84, 366^
368.
[40] Noguchi, E., Shibasaki, M., Nishiyama, C., Okumura, Y. and
Takita, H. (1996) Int. Arch. Allergy Immunol. 110, 380^387.
[41] Yasue, M., Yokota, T., Fukada, M., Takai, T., Suko, M., Oku-
daira, H. and Okumura, Y. (1998) Clin. Exp. Immunol. 113, 1^9.
[42] Kraulis, P.J. (1991) J. Appl. Crystallogr. 24, 946^950.
[43] Merrit, E.A. and Murphy, M.E.P. (1994) Acta Crystallogr. D50,
869^873.
FEBS 24203 26-10-00 Cyaan Magenta Geel Zwart
T. Takai et al./FEBS Letters 484 (2000) 102^107 107
